JP2006508953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508953A5 JP2006508953A5 JP2004550784A JP2004550784A JP2006508953A5 JP 2006508953 A5 JP2006508953 A5 JP 2006508953A5 JP 2004550784 A JP2004550784 A JP 2004550784A JP 2004550784 A JP2004550784 A JP 2004550784A JP 2006508953 A5 JP2006508953 A5 JP 2006508953A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- pancreatic cancer
- synergistic treatment
- pharmaceutically acceptable
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002265 prevention Effects 0.000 claims 4
- 230000002195 synergetic effect Effects 0.000 claims 4
- -1 2-chloro-5-methoxyanilino Chemical group 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 229940122924 Src inhibitor Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 208000032289 susceptibility to 2 pancreatic cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0226434.9A GB0226434D0 (en) | 2002-11-13 | 2002-11-13 | Combination product |
| PCT/GB2003/004787 WO2004043472A1 (en) | 2002-11-13 | 2003-11-07 | Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508953A JP2006508953A (ja) | 2006-03-16 |
| JP2006508953A5 true JP2006508953A5 (enExample) | 2006-12-21 |
Family
ID=9947715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550784A Pending JP2006508953A (ja) | 2002-11-13 | 2003-11-07 | 非受容体チロシンキナーゼのＳｒｃファミリーの阻害剤、および、ゲムシタビンの組み合わせ製品 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060142297A1 (enExample) |
| EP (1) | EP1562612B1 (enExample) |
| JP (1) | JP2006508953A (enExample) |
| KR (1) | KR20050074573A (enExample) |
| CN (1) | CN100467027C (enExample) |
| AT (1) | ATE456370T1 (enExample) |
| AU (1) | AU2003279456B2 (enExample) |
| BR (1) | BR0316170A (enExample) |
| CA (1) | CA2504666A1 (enExample) |
| DE (1) | DE60331162D1 (enExample) |
| ES (1) | ES2338109T3 (enExample) |
| GB (1) | GB0226434D0 (enExample) |
| NO (1) | NO20052312L (enExample) |
| NZ (1) | NZ539514A (enExample) |
| WO (1) | WO2004043472A1 (enExample) |
| ZA (1) | ZA200503805B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| NZ539408A (en) * | 2002-11-04 | 2007-09-28 | Astrazeneca Ab | Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours |
| JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | ｃ−Ｋｉｔキナーゼ阻害剤 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| GB0412074D0 (en) | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| GB0427697D0 (en) | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CN101616671A (zh) | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
| WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| RU2015115397A (ru) | 2012-12-21 | 2017-01-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аморфная форма производного хинолина и способ его получения |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US20170022576A1 (en) | 2015-03-18 | 2017-01-26 | The Regents Of The University Of California | Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| OA11659A (en) * | 1998-09-25 | 2004-12-08 | Warner Lambert Co | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin. |
| DE60006541D1 (de) * | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| GB0101599D0 (en) * | 2001-01-22 | 2001-03-07 | Novartis Ag | Organic compounds |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
-
2002
- 2002-11-13 GB GBGB0226434.9A patent/GB0226434D0/en not_active Ceased
-
2003
- 2003-11-07 US US10/534,721 patent/US20060142297A1/en not_active Abandoned
- 2003-11-07 DE DE60331162T patent/DE60331162D1/de not_active Expired - Lifetime
- 2003-11-07 EP EP03772404A patent/EP1562612B1/en not_active Expired - Lifetime
- 2003-11-07 NZ NZ539514A patent/NZ539514A/en unknown
- 2003-11-07 BR BR0316170-6A patent/BR0316170A/pt not_active IP Right Cessation
- 2003-11-07 ES ES03772404T patent/ES2338109T3/es not_active Expired - Lifetime
- 2003-11-07 CA CA002504666A patent/CA2504666A1/en not_active Abandoned
- 2003-11-07 KR KR1020057008291A patent/KR20050074573A/ko not_active Withdrawn
- 2003-11-07 AT AT03772404T patent/ATE456370T1/de not_active IP Right Cessation
- 2003-11-07 CN CNB2003801031384A patent/CN100467027C/zh not_active Expired - Fee Related
- 2003-11-07 WO PCT/GB2003/004787 patent/WO2004043472A1/en not_active Ceased
- 2003-11-07 AU AU2003279456A patent/AU2003279456B2/en not_active Ceased
- 2003-11-07 JP JP2004550784A patent/JP2006508953A/ja active Pending
-
2005
- 2005-05-11 ZA ZA200503805A patent/ZA200503805B/en unknown
- 2005-05-11 NO NO20052312A patent/NO20052312L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508953A5 (enExample) | ||
| NO2020026I1 (no) | Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet | |
| JP2007536311A5 (enExample) | ||
| BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
| TW200505924A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| WO2005005414A3 (en) | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| NO20076613L (no) | Farmasoytiske formuleringer og anvendelse derav | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
| PH12013502277A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| NO20090443L (no) | 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| WO2005014572A8 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| NO20073403L (no) | Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 | |
| JP2018090566A5 (enExample) | ||
| TW200624431A (en) | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы |